BRPI0816994B8 - derivado uracila ou timina para tratar hepatite c - Google Patents

derivado uracila ou timina para tratar hepatite c

Info

Publication number
BRPI0816994B8
BRPI0816994B8 BRPI0816994A BRPI0816994A BRPI0816994B8 BR PI0816994 B8 BRPI0816994 B8 BR PI0816994B8 BR PI0816994 A BRPI0816994 A BR PI0816994A BR PI0816994 A BRPI0816994 A BR PI0816994A BR PI0816994 B8 BRPI0816994 B8 BR PI0816994B8
Authority
BR
Brazil
Prior art keywords
uracil
compounds
dioxo
butyl
derivative
Prior art date
Application number
BRPI0816994A
Other languages
English (en)
Portuguese (pt)
Inventor
C Krueger Allan
R Haight Anthony
J Kotecki Brian
A Flentge Charles
E Motter Christopher
J Maring Clarence
Liu Dachun
A Betebenner David
A Degoey David
M Barnes David
K Hutchinson Douglas
G Z Zhang Geoff
E Hengeveld John
K Pratt John
T Randolph John
Sarris Kathy
D Stewart Kent
L Longenecker Kenton
D Tufano Michael
L Donner Pamela
P Huang Peggy
F Henry Rodger
Chen Shuang
S Franczyk Ii Thaddeus
W Rockway Todd
Rolf Wagner
M Kati Warren
Lou Xiaochun
Liu Yaya
Gao Yi
Original Assignee
Abbott Lab
Abbvie Bahamas Ltd
Abbvie Inc
Abbvie Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0816994(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Abbvie Bahamas Ltd, Abbvie Inc, Abbvie Ireland Unlimited Co filed Critical Abbott Lab
Publication of BRPI0816994A2 publication Critical patent/BRPI0816994A2/pt
Publication of BRPI0816994B1 publication Critical patent/BRPI0816994B1/pt
Publication of BRPI0816994B8 publication Critical patent/BRPI0816994B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
BRPI0816994A 2007-09-17 2008-09-17 derivado uracila ou timina para tratar hepatite c BRPI0816994B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97287707P 2007-09-17 2007-09-17
US9679108P 2008-09-13 2008-09-13
PCT/US2008/076576 WO2009039127A1 (en) 2007-09-17 2008-09-17 Uracil or thymine derivative for treating hepatitis c

Publications (3)

Publication Number Publication Date
BRPI0816994A2 BRPI0816994A2 (pt) 2015-03-24
BRPI0816994B1 BRPI0816994B1 (pt) 2019-12-24
BRPI0816994B8 true BRPI0816994B8 (pt) 2021-05-25

Family

ID=39948002

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816994A BRPI0816994B8 (pt) 2007-09-17 2008-09-17 derivado uracila ou timina para tratar hepatite c

Country Status (30)

Country Link
US (3) US8415351B2 (show.php)
EP (2) EP2725015A1 (show.php)
JP (2) JP5734654B2 (show.php)
KR (2) KR101552474B1 (show.php)
CN (2) CN101801935B (show.php)
AR (2) AR070027A1 (show.php)
AU (1) AU2008302448B2 (show.php)
BR (1) BRPI0816994B8 (show.php)
CA (2) CA2976793A1 (show.php)
CL (2) CL2008002794A1 (show.php)
CO (1) CO6260076A2 (show.php)
CR (2) CR11316A (show.php)
DO (2) DOP2010000084A (show.php)
ES (1) ES2453591T3 (show.php)
GT (1) GT201000061A (show.php)
IL (1) IL204547A (show.php)
IN (1) IN2012DN05113A (show.php)
MX (2) MX2010002905A (show.php)
MY (1) MY162760A (show.php)
NZ (3) NZ600371A (show.php)
PA (1) PA8796201A1 (show.php)
PE (2) PE20130209A1 (show.php)
PH (1) PH12013500365A1 (show.php)
RU (2) RU2543620C2 (show.php)
SG (1) SG183733A1 (show.php)
TW (2) TWI534137B (show.php)
UA (1) UA117800C2 (show.php)
UY (1) UY31344A1 (show.php)
WO (1) WO2009039127A1 (show.php)
ZA (2) ZA201204224B (show.php)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203431B1 (en) * 2007-09-17 2011-08-10 Abbott Laboratories Anti-infective pyrimidines and uses thereof
DK2203430T3 (da) 2007-09-17 2011-09-26 Abbott Lab N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
SG183733A1 (en) 2007-09-17 2012-09-27 Abbott Lab Uracil or thymine derivative for treating hepatitis c
JP5249344B2 (ja) * 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の３位が置換されたインドール誘導体およびその使用
JP2011528686A (ja) 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス性化合物
JP2012503620A (ja) 2008-09-26 2012-02-09 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖを処置するためのピリンまたはピラジン誘導体
BRPI1009854A2 (pt) * 2009-03-24 2015-08-25 Abbott Lab Processo para preparar composto antiviral
EP2421845B1 (en) * 2009-03-25 2013-04-17 Abbott Laboratories Antiviral compounds and uses thereof
US20120065247A1 (en) * 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
JP2012524752A (ja) 2009-04-25 2012-10-18 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
EP2445875A2 (en) * 2009-06-24 2012-05-02 F. Hoffmann-La Roche AG Heterocyclic antiviral compound
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
CN102498100A (zh) 2009-09-21 2012-06-13 弗·哈夫曼-拉罗切有限公司 抗病毒杂环化合物
MX2012005706A (es) * 2009-11-21 2012-06-12 Hoffmann La Roche Compuestos antivirales heterociclicos.
AR079440A1 (es) 2009-12-14 2012-01-25 Hoffmann La Roche Compuestos heterociclicos antivirales
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
RU2572558C2 (ru) 2010-07-07 2016-01-20 Ф. Хоффманн-Ля Рош Аг Противовирусные гетероциклические соединения
AU2015201698B2 (en) * 2010-07-16 2017-02-02 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
KR101774742B1 (ko) 2010-07-16 2017-09-11 애브비 아일랜드 언리미티드 컴퍼니 촉매 반응용 포스핀 리간드
EP3415504A1 (en) 2010-07-16 2018-12-19 AbbVie Ireland Unlimited Company Process for preparing antiviral compounds
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
MX2013001273A (es) 2010-08-13 2013-04-10 Hoffmann La Roche Compuestos heterociclicos antivirales.
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
TWI558400B (zh) 2011-03-18 2016-11-21 艾伯維有限公司 苯基尿嘧啶化合物之調配物
US20140065223A1 (en) * 2011-03-31 2014-03-06 Jeanette Libera-Koerner Perfluorinated compounds for the non-viral transfer of nucleic acids
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5734124B2 (ja) * 2011-07-21 2015-06-10 株式会社 東邦アーステック １，３−ジヨードヒダントイン類の製造方法
US9040516B2 (en) 2011-08-01 2015-05-26 Sumitomo Dainippon Pharma Co., Ltd. Uracil derivative and use thereof for medical purposes
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
JP6078640B2 (ja) 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
WO2013171641A1 (en) 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
KR102091893B1 (ko) 2012-05-15 2020-03-23 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
JP6204975B2 (ja) 2012-05-15 2017-09-27 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
EP2866807A2 (en) 2012-06-27 2015-05-06 Abbvie Inc. Methods for treating hcv
MX360161B (es) * 2012-08-21 2018-10-09 Abbvie Inc Proceso para preparar compuestos antiviricos.
US9629841B2 (en) * 2012-10-18 2017-04-25 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
CA2916912A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
WO2015004028A1 (de) 2013-07-08 2015-01-15 Bayer Cropscience Ag Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel
US10149859B2 (en) 2013-09-11 2018-12-11 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20150209403A1 (en) 2014-01-28 2015-07-30 Abbvie Inc. Dose Adjustment
HUE045511T2 (hu) 2014-02-03 2020-01-28 Vitae Pharmaceuticals Llc A ror-gamma dihidro-pirrolopiridin inhibitorai
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
US10752640B2 (en) 2014-08-01 2020-08-25 Nuevolution A/S Compounds active towards bromodomains
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
EP3207043B3 (en) 2014-10-14 2019-10-02 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2016196280A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Heterocycle-substituted bicyclic pesticides
US10517870B2 (en) * 2015-07-30 2019-12-31 Bristol-Myers Squibb Company Aryl substituted bicycle heteroaryl compounds
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
CN108463458B (zh) 2015-11-20 2022-02-01 生命医药有限责任公司 ROR-γ的调节剂
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN115716826A (zh) 2017-07-24 2023-02-28 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN107266373A (zh) * 2017-08-01 2017-10-20 安徽拜善晟制药有限公司 一种原料药达沙布韦的制备方法
CN118754858A (zh) 2018-03-26 2024-10-11 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5162326A (en) 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (show.php) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
HK1054384B (zh) 1999-12-06 2005-12-09 霍夫曼-拉罗奇有限公司 4-嘧啶基-n-酰基-l-苯基丙氨酸类化合物
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
IL167954A (en) * 2000-02-04 2007-10-31 Sumitomo Chemical Co History of pyrimidine
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JO2934B1 (en) * 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
SG183733A1 (en) * 2007-09-17 2012-09-27 Abbott Lab Uracil or thymine derivative for treating hepatitis c
EP2203431B1 (en) * 2007-09-17 2011-08-10 Abbott Laboratories Anti-infective pyrimidines and uses thereof
DK2203430T3 (da) 2007-09-17 2011-09-26 Abbott Lab N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
JP2011528686A (ja) 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス性化合物

Also Published As

Publication number Publication date
NZ600371A (en) 2014-07-25
AU2008302448A1 (en) 2009-03-26
AR087472A2 (es) 2014-03-26
BRPI0816994B1 (pt) 2019-12-24
RU2010114828A (ru) 2011-10-27
US8415351B2 (en) 2013-04-09
WO2009039127A1 (en) 2009-03-26
AR070027A1 (es) 2010-03-10
NZ584720A (en) 2012-07-27
RU2599635C2 (ru) 2016-10-10
TWI534137B (zh) 2016-05-21
CO6260076A2 (es) 2011-03-22
US8685991B2 (en) 2014-04-01
KR101660360B1 (ko) 2016-09-27
MY162760A (en) 2017-07-14
TWI437994B (zh) 2014-05-21
KR20150117632A (ko) 2015-10-20
JP2010539186A (ja) 2010-12-16
US20140235638A1 (en) 2014-08-21
AU2008302448B2 (en) 2014-11-06
DOP2010000396A (es) 2013-12-31
CL2008002794A1 (es) 2009-09-04
ZA201204223B (en) 2015-12-23
JP5734654B2 (ja) 2015-06-17
US20120213733A1 (en) 2012-08-23
UA117800C2 (uk) 2018-10-10
KR20100068289A (ko) 2010-06-22
US20110070193A1 (en) 2011-03-24
EP2222646B1 (en) 2014-01-22
PE20130209A1 (es) 2013-03-24
TW200918066A (en) 2009-05-01
BRPI0816994A2 (pt) 2015-03-24
MX338555B (es) 2016-04-20
RU2013104270A (ru) 2014-08-10
ES2453591T3 (es) 2014-04-08
US9095590B2 (en) 2015-08-04
PH12013500365A1 (en) 2014-09-08
HK1147256A1 (en) 2011-08-05
CN102746239B (zh) 2016-02-10
NZ618277A (en) 2015-07-31
GT201000061A (es) 2012-03-26
UY31344A1 (es) 2009-04-30
TW201443027A (zh) 2014-11-16
SG183733A1 (en) 2012-09-27
CN101801935B (zh) 2014-12-03
CR20150238A (es) 2015-07-01
MX2010002905A (es) 2010-07-05
KR101552474B1 (ko) 2015-09-11
ZA201204224B (en) 2015-12-23
CN102746239A (zh) 2012-10-24
CA2976793A1 (en) 2009-03-26
JP2013049681A (ja) 2013-03-14
CA2699981C (en) 2017-08-22
IL204547A0 (en) 2010-11-30
IN2012DN05113A (show.php) 2015-10-23
PA8796201A1 (es) 2009-04-23
CL2013000372A1 (es) 2013-10-04
DOP2010000084A (es) 2010-06-15
RU2543620C2 (ru) 2015-03-10
PE20090705A1 (es) 2009-07-17
EP2222646A1 (en) 2010-09-01
CN101801935A (zh) 2010-08-11
CA2699981A1 (en) 2009-03-26
CR11316A (es) 2010-10-05
EP2725015A1 (en) 2014-04-30
IL204547A (en) 2016-04-21

Similar Documents

Publication Publication Date Title
BRPI0816994B8 (pt) derivado uracila ou timina para tratar hepatite c
ATE512973T1 (de) Nukleosid-arylphosphoramidate und ihre verwendung als antivirale mittel zur behandlung von hepatitis-c-virus
DE602005013922D1 (de) Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
BR0316407A (pt) Derivados de nucleosìdeo antiviral
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
UA99484C2 (ru) Производные пиримидина для лечения астмы, хронического обструктивного заболевания легких, аллергических ринитов, аллергических коньюктивитов, атопических дерматитов, рака, гепатита b, гепатита c, вич, вируса папилломы человека, бактериальных инфекций и дерматозов
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
BR112014027181A2 (pt) derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
MA33642B1 (fr) Composés chimiques
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
DE602005023015D1 (de) Indolderivate als viruzide
EA200901241A1 (ru) Соединения для лечения гепатита с
TN2010000291A1 (fr) Inhibiteurs de polymerase virale
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
BRPI0406646A (pt) Compostos de(2-carboxamido)(3-amina)tiofenos, bem como composições e usos compreendendo os mesmos
BRPI0614493B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto
BR0215016A (pt) Piridoquinoxalinas antivirìcas
BR0209677A (pt) Composto, processo para preparar e uso do mesmo, composição farmacêutica, e, métodos para o tratamento da dor, de distúrbios gastrintestinais funcionais e da ansiedade
EA200970615A1 (ru) Соединения имидазолидинониламинопиримидина для лечения рака
ATE491706T1 (de) Heterocyclische antivirale verbindungen

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B25A Requested transfer of rights approved

Owner name: ABBVIE BAHAMAS LTD. (US)

B25A Requested transfer of rights approved

Owner name: ABBVIE IRELAND UNLIMITED COMPANY (BM)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF